Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UspA2 protein is a large, coiled-coil, trimeric autotransporter adhesin (~62 kDa monomer, forms high-molecular-weight oligomers)[4] presented on the surface of nearly all clinical isolates of *M. catarrhalis*[1][4][5]. UspA2 confers resistance to complement-mediated killing by binding human serum proteins such as vitronectin, C4b-binding protein, factor H, and plasminogen, thereby preventing membrane attack complex (MAC) formation and promoting survival in the human host[1][5]. It also contributes to bacterial adhesion to host cells via host receptor and ECM protein (vitronectin and integrins) binding[3]. UspA2 is immunogenic and a target for vaccine development; its exposed domains are recognized by biologically active antibodies[1][2][3][4][5]. Genetic exchange and recombination within the UspA family (including UspA1, UspA2, and hybrid forms) drive antigenic diversity and may influence functional properties related to adhesion and immune evasion[2][3].
Experimental drugs/fusion proteins block complement evasion by binding UspA2 to enhance complement-mediated bacterial killing
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UspA2 protein (UspA2).